Cost-utility of as-needed combination low-dose budesonide-formoterol in adolescents mild asthma.

In conclusion, low-dose budesonide-formoterol as a reliever was found to be cost-effective when added to usual care in adolescents with mild asthma. This evidence should promote economic evaluations in developed and developing countries for the inclusion of new drugs in health insurance plans.